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Abstract
Lung cancer is the leading cause of cancer mortality in the world today. Although some advances in lung cancer
therapy have been made, patient survival is still poor. MicroRNAs (miRNAs) can act as oncogenes or tumor-
suppressor genes in human malignancy. The miR-34 family consists of tumor-suppressive miRNAs, and its reduced
expression has been reported in various cancers, including non-small cell lung cancer (NSCLC). In this study, we
found that miR-34a and miR-34c target platelet-derived growth factor receptor alpha and beta (PDGFR-α and
PDGFR-β), cell surface tyrosine kinase receptors that induce proliferation, migration and invasion in cancer. MiR-34a
and miR-34c were downregulated in lung tumors compared to normal tissues. Moreover, we identified an inverse
correlation between PDGFR-α/β and miR-34a/c expression in lung tumor samples. Finally, miR-34a/c overexpression
or downregulation of PDGFR-α/β by siRNAs, strongly augmented the response to TNF-related apoptosis inducing
ligand (TRAIL) while reducing migratory and invasive capacity of NSCLC cells.
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Introduction
Lung cancer is the most common cause of cancer death
worldwide [1]. Despite years of research, the prognosis for
patients with lung cancer remains dismal. The most frequent
type, non-small cell lung cancer (NSCLC) (85%), shows an
overall five year survival of 15%. Isoforms of platelet-derived
growth factor receptor (PDGFR) and its ligand, PDGF,
constitute a family of receptors and ligands involved in
proliferative and prosurvival signaling within cells. The PDGFR/
PDGF system includes two receptors (PDGFR-α and PDGFR-
β) and four ligands (PDGFA, PDGFB, PDGFC, and PDGFD).
Ligand binding induces receptor dimerization, enabling
autophosphorylation of specific tyrosine residues and
subsequent recruitment of a variety of signal transduction
molecules. PDGFR regulates normal cellular growth and
differentiation [2] and expression of activated PDGFR promotes
oncogenic transformation [3]. Numerous in vitro and in vivo
studies showed that inhibition of PDGFR-α signaling disrupts
cancer cell survival in the subset of gastrointestinal stromal
tumors (GISTs) with activating PDGFR-α mutations [4,5]. In a
recent study of 150 NSCLC patient samples, activated
PDGFR-α was detected in 13% of cases [6], suggesting that a
subset of these patients might benefit from therapies directed
against PDGFR-α. Moreover, PDGFR-α overexpression has
been observed in metastatic versus nonmetastatic
medulloblastoma patient samples and disrupting PDGFR-α
function inhibited the metastatic potential of medulloblastoma
cells in vitro [7]. Given its progrowth role in cell signaling,
PDGFR-α has become an attractive therapeutic target in a
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number of human malignancies. In non–small cell lung cancer,
cytoplasmic PDGFR-α expression by tumor is a negative
prognostic indicator [8], confirming that the PDGF axis may be
biologically relevant. All members of the PDGF family display
potent angiogenic activity in vivo, and from this point of view,
PDGF-B/PDGFRβ axis was the most extensive evaluated. In
the null mice it was shown that PDGF-B and PDGFRβ are
critically involved in vascular development. The role of PDGF/
PDGFR in vascular development is supported by knockout
experiments [9,10]. MicroRNAs (miRNAs), a class of ~ 22 nt
endogenous RNAs, are important regulators of gene
expression and have been implicated in the regulation of
critical processes that are deregulated in cancer cells, as
proliferation [11] differentiation [12] and apoptosis [13].
Alterations in miRNA expression in cancer have been
documented in numerous studies and suggest that miRNAs
critically contribute to the cancer cell phenotype [14,15].
Furthermore, some miRNA-encoding genes have been
classified as oncogenic or tumor suppressive genes according
to their function in cellular transformation and altered
expression in tumors.
In 2007, reports from several laboratories showed that
members of the miR-34 family are direct p53 targets, and that
their upregulation induced apoptosis and cell-cycle arrest
[16,17]. In mammalians, the miR-34 family comprises three
processed miRNAs that are encoded by two different genes:
miR-34a is encoded by its own transcript, whereas miR-34b
and miR-34c share a common primary transcript. Moreover,
the promoter region of miR-34a, miR-34b and miR-34c
contains CpG islands and aberrant CpG methylation reduces
miR-34 family expression in multiple types of cancer [18,19,20].
In this study, we show that miR-34a and miR-34c, are
strongly downregulated in NSCLC cells and lung tumors
whereas they are highly expressed in normal lung tissues.
Moreover, miR-34a and miR-34c, by targeting PDGFR-α and
PDGFR-β, increase TRAIL-induced apoptosis and decrease
invasiveness of lung cancer cells. Furthermore, our results
suggest, for the first time, that combinatory treatment of TRAIL
and PDGFR inhibitors could be effective for anti-NSCLC
therapy.
Results
MiR-34a and miR-34c target PDGFR-α and PDGFR-β 3’
UTRs
Among the miRNAs, miR-34 family members play important
tumor suppressive roles, as they are directly regulated by p53
and compose the p53 network [16,17]. A previous study
indicated that miR-34 methylation was present in NSCLC and
was significantly related to an unfavorable clinical outcome
[20]. First, we analyzed by Real Time PCR (qRT-PCR)
miR-34a, -34b and -34c expression in 5 different NSCLC cell
lines with p53 WT, mutant or null (Figure S1a in File S1).
MiR-34a, -34b and -34c had low or absent expression in all the
five cell lines (Figure S1b in File S1). To identify miR-34a, -34b,
and -34c targets, we performed a bioinformatics search
(Targetscan, Pictar) for putative mRNA targets. Among the
candidate targets, 3’ UTR of human PDGFR-α and PDGFR-β
contained regions (PDGFR-α nucleotides 2670–2676;
2699-2705; PDGFR-β nucleotides 1535-1541) that matched
the seed sequences of hsa-miR-34a, -34b and -34c (Figure
1a). PDGFR-α and PDGFR-β have been reported to be
overexpressed and related to poor outcome in lung cancer [21].
To verify whether PDGFR-α and PDGFR-β were direct targets
of miR-34a, -34b and -34c, PDGFR-α 3’ UTR, containing two
miR-34a, -34b and -34c binding sites and PDGFR-β 3’ UTR,
containing one miR-34a, -34b and -34c binding site (Figure
1a,b), were cloned downstream of the luciferase open reading
frame. Interestingly, increased expression of miR-34a and
miR-34c, and not miR-34b, upon transfection, confirmed by
qRT-PCR (data not shown), significantly decreased luciferase
activity, indicating a direct interaction between the miRNAs and
PDGFRα and PDGFRβ 3’ UTRs (Figure 1c,d). Target gene
repression was rescued by mutations in the complementary
seed sites (Figure 1b,c,d). Taken together the results indicate
that miR-34a and miR-34c and not miR-34b directly target
PDGFR-α and PDGFR-β.
MiR-34a and miR-34c are inversely related to PDGFR-α/
β expression in vitro and in vivo
Next, we analyzed the consequences of the ectopic
expression of miR-34a and -34c in Calu-6 and H1703 cells. We
chose these two cell lines because of the high expression
levels of PDGFR-α (H1703 and Calu-6) and PDGFR-β (Calu-6)
(data not shown). Increased expression of miR-34a and
miR-34c upon transfection was confirmed by qRT-PCR (data
not shown) and then the effects on PDGFR-α and PDGFR-β
mRNA and protein levels were analyzed by qRT-PCR and
western blot. MiR-34a and -34c (and not miR-34b)
overexpression significantly reduced PDGFR-α and PDGFR-β
mRNAs (Figure 2a) and the endogenous protein levels,
compared to the cells transfected with a scrambled pre-miR
(Figure 2b). The expression levels of the four PDGF ligands
(PDGFA, PDGFB, PDGFC, PDGFD) after miR-34a and
miR-34c enforced expression were also evaluated in both
Calu-6 and H1703 cells. PDGFD was barely expressed in both
cell lines; we did not find any variation of the expression of
PDGFA, PDGFB and PDGFC (data not shown). In summary,
these results supported the bioinformatics predictions
indicating PDGFR-α and PDGFR-β 3’ UTRs as targets of
miR-34a and -34c.
To verify the downregulation of miR-34a and -34c also in
vivo, 9 lung tumors (among adenocarcinoma and squamous
cell carcinoma) and the adjacent histologically normal lung
tissues were analyzed for miR-34a and -34c expression. As
shown in Figure 3a and b, miR-34a and miR-34c expression
was lower in the tumor compared to the normal samples
(Figure 3a,b).
Moreover, we analyzed miR-34a, 34c and PDGFR-α/β
mRNA expression in 24 primary human lung tumor specimens
in comparison with 24 normal tissues. MiR-34a and -34c were
almost undetectable in the tumor and highly expressed in the
normal lung samples tested (Figure 3c). Remarkably, an
inverse correlation between miR-34a/c and PDGFR-α and
PDGFR-β was observed (Figure 3d). To further corroborate
these findings, in situ hybridization (ISH) analysis was
miR-34a/c Induce TRAIL Sensitivity
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67581
performed using 5’-dig-labeled LNA probes on lung tumors and
normal tissues, followed by immunohistochemistry (IHC) for
PDGFR-α and PDGFRβ. Most lung cancer cells showed low
expression of miR-34a and high expression of PDGFR-α/β,
whereas the adjacent non-malignant lung expressed PDGFR-α
rarely and abundantly expressed miR-34a. MiR-34a and
PDGFR-α/β expression in the majority of the 107 different
tumors analyzed was basically mutually exclusive (Figure 4a,b
and Figure S2 in File S1).
MiR-34a and miR-34c overcome TRAIL resistance of
NSCLC cells through PDGFR-α and PDGFR-β
downregulation
TNF-related apoptosis-inducing ligand (TRAIL) is a member
of the tumor necrosis factor family, known to induce apoptosis
in a variety of different tumor types. TRAIL is able to
specifically induce cell death in cancer cells while sparing
normal cells and is currently being tested as a promising anti-
tumor agent in clinical trials [22]. However, many tumors
including NSCLC are resistant to TRAIL thus limiting its
therapeutic application. Since PDGFR-α and PDGFR-β
regulate the PI3K/Akt and ERK1/2 pathways [23,24,25], we
Figure 1.  MiR-34a and miR-34c target PDGFR-α and PDGFR-β 3’ UTRs.  (a) PDGFR-α and PDGFR-β 3’ UTRs contain,
respectively, two and one predicted miR-34a, -34b and -34c binding sites. In the figure the alignment of the seed regions of
miR-34a/c with PDGFR-α and PDGFR-β 3’ UTRs is shown. The sites of target mutagenesis are indicated in red. _deleted
nucleotides. (b) PGL3 control-PDGFR-α constructs containing two PDGFR-α binding sites (in red). Deletion of one of the two
PDGFR-α sites was used to generate the mutant luciferase palsmids. (c–d) PDGFR-α and PDGFR-β 3’ UTRs are direct targets of
miR-34a and miR-34c. pGL3-PDGFR-α and pGL3-PDGFR-β luciferase constructs, containing a wild-type (left side of the
histograms) or mutated (right side of the histograms) PDGFR-α and PDGFR-β 3’ UTRs, were transfected into Calu-6 cells. Relative
repression of firefly luciferase expression was standardized to a transfection control. The reporter assays were performed three
times with essentially identical results. *P<0.0001, **P<0.05 by two tailed Student’s t test.
doi: 10.1371/journal.pone.0067581.g001
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next examined, by immunostaining, the expression and/or
activation of some of the proteins involved in these pathways
following miR-34a and miR-34c enforced expression or
PDGFR-α/β silencing by siRNAs. As shown in Figure 5a,
phosphorylation levels of ERKs decreased after miR-34a and
miR-34c enforced expression compared to cells transfected
with the control miR. PDGFR-α silencing reduced the activation
of both Akt and ERK1/2 (Figure 5b). We previously
demonstrated that the PI3K/AKT pathway plays a key role in
TRAIL-induced apoptosis [26], therefore the effects of miR-34a
and miR-34c overexpression on cell survival and TRAIL
resistance of NSCLC were examined. First, we performed a
proliferation assay on Calu-6 and H1703 TRAIL semi-resistant
cells after enforced expression of miR-34a and miR-34c. 48h
after transfection cells were exposed to TRAIL for 24h and then
cell proliferation was assessed using an MTT assay. Calu-6
and H1703 cells overexpressing miR-34a and -34c showed a
significant lower proliferation rate compared to the control cells
(Figure S3a in File S1). Moreover, caspase 3/7 assay revealed
an increase in TRAIL sensitivity after miR-34a and -34c
enforced expression or PDGFR-α/β silencing, compared to the
cells transfected with a scrambled miR or siRNA (Figure 5c,d).
Furthermore, overexpression of PDGFR-α and PDGFR-β in
H460 TRAIL-sensitive cells, increased the resistance to the
drug (Figure 5e and Figure S3c in File S1). Conversely,
treatment of Calu-6 cells with a PDGFR inhibitor significantly
increased the sensitivity to TRAIL-induced apoptosis (Figure 5f
and Figure S3d in File S1). Intriguingly, overexpression of
PDGFR-α or PDGFR-β (using two plasmids containing only the
coding sequences and not the 3’ UTRs of PDGFR-α/β) along
with miR-34a or miR-34c, decreased the sensitivity to TRAIL-
induced apoptosis, as assessed by both MTT and caspase 3/7
assay (Figure S4 in File S1). The results suggest that PDGFR-
α and PDGFR-β play an important role in TRAIL-induced
Figure 2.  MiR-34a and miR-34c reduce PDGFR-α and PDGFR-β mRNA and protein levels.  (a) qRT-PCR showing PDGFR-α
and PDGFR-β mRNAs downregulation in Calu-6 and H1703 cells after miR-34 and miR-34c but not miR-34b enforced expression
(b) miR-34a and miR-34c enforced expression decreases endogenous levels of PDGFR-α/β protein levels in H1703 and Calu-6
NSCLC. Cells were transfected with either scrambled, miR-34a or miR-34c for 72h. PDGFR-α and PDGFR-β expression was
assessed by western blot. Loading control was obtained using GAPDH antibody. *P<0.05, **P<0.001 by two tailed Student’s t test.
doi: 10.1371/journal.pone.0067581.g002
miR-34a/c Induce TRAIL Sensitivity
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e67581
Figure 3.  MiR-34a/c and PDGFR-α/β are inversely correlated in normal and tumor lung tissue samples.  (a–b) qRT-PCR on
18 lung tumor and normal tissues. MiR-34a and miR-34c are downregulated in the tumors compared to the normal lung tissues. (c)
Box plots showing miR-34a and miR-34c expression in 48 lung normal and cancer tissues. (d) XY scatter plots showing inverse
correlation between miR-34a/c and PDGFR-α/β. Two-tailed Student’s t test was used to verify the significance. P<0.05.
doi: 10.1371/journal.pone.0067581.g003
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apoptosis and that PDGFR inhibitor can sensitize NSCLC cells
to TRAIL with important therapeutic consequences.
PDGFR-α/β downregulation by miR-34a and miR-34c
inhibits migration and invasiveness of NSCLC cells
Because PDGFR-α/β regulate the PI3K/AKT pathway,
notably involved in migration and invasion of different tumors
[27,28], we investigated if miR-34a/c could influence NSCLC
migration and invasion through PDGFR-α and PDGFR-β
downregulation. To directly test the functional role of miR-34a/c
in tumorigenesis, we overexpressed these two miRNAs or
silenced PDGFR-α/β in Calu-6 or H1703 cells. Intriguingly, we
observed a significant decrease of the migratory and invasive
capabilities of Calu-6 and H1703 cells after miR-34a or
miR-34c overexpression (Figure 6a) as well after PDGFR-α
and PDGFR-β downregulation (Figure 6b), confirmed also by
scratch-wound assay (Figure 6c). To further verify that
PDGFR-α and PDGFR–β were involved in tumorigenesis of
NSCLC cells, miR-34a and -34c were transfected in Calu-6
cells alone or in combination with a plasmid overexpressing
only the coding sequence and not the 3’ UTR of PDGFR-α and
PDGFR-β. MiR-34a/c enforced expression reduced migration
and invasion of Calu-6 cells but overexpression of PDGFR-α or
Figure 4.  MiR-34a/c and PDGFR-α/β co-expression in vivo.  (a–b) Immunohistochemistry and in situ hybridization on 107 lung
cancer tissues samples. MiR-34a (blue) and PDGFR-α/β (brown/red, respectively in RGB and each fluorescent red in Nuance
converted image) expression was inversely related in lung cancers and the adjacent normal lung tissues. These serial sections were
analyzed for miR-34a expression by in situ hybridization, followed by immunohistochemistry for PDGFR-α/β. (a) Representative
example: Co-expression analysis of miR-34a and PDGFR-α. Note lack of expression in the merged image (panel b) (fluorescent
yellow = co-expression). (b) Representative example: miR-34a= blue (panel a), PDGFR-β=red (panel b), co-expression= yellow
(panel c). RGB= Regular Green Blue image of the ISH/lHC reaction shown in panels a-c. Scale bar indicates 50 μm. The
magnification is the same for all the panels.
doi: 10.1371/journal.pone.0067581.g004
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Figure 5.  MiR-34a and miR-34c overexpression or PDGFR-α/β silencing increases the response of NSCLC cells to TRAIL-
induced apoptosis.  (a) Western blot in Calu-6 cells after miR-34a, -34b and -34c forced expression. MiR-34a or miR-34c and not
miR-34b forced expression decreases PDGFRβ expression levels and reduces the activation of the ERK1/2. (b) Western blot
showing the inactivation of the Akt and ERKs pathways after PDGFR-α silencing. (c) Caspase 3/7 assay. MiR-34a and -34c
enforced expression in Calu-6 and H1703 semi-resistant cells, increases the response to TRAIL-induced apoptosis. (d) Caspase
3/7 assay showing that PDGFR-α or PDGFR-β silencing increases the response to TRAIL-induced apoptosis. (e) PDGFR-α or
PDGFR-β overexpression in H460 TRAIL-sensitive cells decreases the response to the drug. (f) Combined treatment of PDGFR
inhibitor (20 μM) and different TRAIL concentrations (0-100-150 ng/ml) for 24h sensitizes NSCLC cells to TRAIL-induced apoptosis.
*P<0.001, ** P<0.05.
doi: 10.1371/journal.pone.0067581.g005
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PDGFR-β, along with the two microRNAs, partially restored the
migration and invasion capabilities, suggesting that miR-34a/c
regulate NSCLC tumorigenesis, at least in part, through
PDGFR-α/ β (Figure 6 d,e).
Discussion
Lung cancer is the leading cause of cancer death in both
men and women worldwide1. The American cancer Society
estimates 156,940 deaths from lung cancer in the United
States for 2011 alone [29]. Non-small cell lung cancer (NSCLC)
accounts for the majority of all lung cancer cases and is a
leading cause of cancer mortality [30].
The high mortality rate associated with lung cancer has
prompted numerous exhaustive efforts to identify novel
therapeutic targets and treatment modalities for this deadly
disease. Platelet-derived growth factor receptors (PDGFRs)
and their ligands, platelet-derived growth factors (PDGFs) play
critical roles in mesenchymal cell migration and proliferation.
Abnormalities of PDGFR/PDGF are thought to contribute to a
number of human diseases and especially malignancy [31].
MicroRNAs are small noncoding RNAs that show
deregulation in most cancers. There is growing evidence that
they play substantial roles in the pathogenesis and prognosis
of human malignancies and in the resistance to
chemotherapeutic drugs [32,33]. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) triggers apoptosis in tumor
Figure 6.  MiR-34a and miR-34c overexpression or PDGFR-α/β silencing decreases migratory and invasive capacity of
NSCLC cells.  (a) MiR-34a and -34c enforced expression reduces migratory and invasive capabilities of H1703 cells. (b) PDGFR-α
and PDGFR-β silencing reduces migratory and invasive capabilities of Calu-6 cells. RFU= Relative Fluorescence Units. (c)
Representative photographs of scratched areas of the confluent monolayer of Calu-6 cells transfected with miR-34a/c or control
miRNA (miR-Ctr) at 0h, 12h and 24h after wounding with a pipet tip. Scale bar, 100 μm. The magnification is the same for all the
panels. (d–e) PDGFR-α and PDGFR-β overexpression partially rescues migratory and invasive capabilities of Calu-6 cells. *
P<0.05.
doi: 10.1371/journal.pone.0067581.g006
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cells, but when used alone, it is ineffective at treating TRAIL-
resistant tumors. This resistance is challenging for TRAIL-
based anti-cancer therapies. In this study, we found that
miR-34a and miR-34c are strongly downmodulated in both
NSCLC cells and lung tumors compared to normal tissues.
Enforced expression of miR-34a and miR-34c downregulated
PDGFR-α and PDGFR-β mRNA and protein levels. Luciferase
and western blot experiments demonstrated that PDGFR-α and
PDGFR-β are direct targets of miR-34a and miR-34c but not of
miR-34b. The resistance of many types of cancer to
conventional chemotherapies is a major factor undermining
successful cancer treatment. AKT activation also contributes to
tumorigenesis and tumor metastasis, and as shown most
recently, resistance to chemotherapy [26,34]. As a result, both
in vitro and in vivo studies combining small molecule inhibitors
of the PI3K/Akt pathway with standard chemotherapy have
proven successful in attenuating chemotherapeutic resistance.
Specifically, inhibiting AKT activity may be a valid approach to
treat cancer and increase the efficacy of chemotherapy.
Protein kinases are major regulators of most cellular
signaling pathways. Among them, receptor tyrosine kinases
(RTKs), such as PDGFR, play pivotal roles in promoting
cellular growth and proliferation by transducing extracellular
stimuli to intracellular signaling circuits [35]. A prominent
component of the intracellular signaling machinery is the PI3K/
Akt(PKB)/mammalian target of rapamycin (PI3K/Akt[PKB]/
mTOR) pathway [36,37]. Aberrant activation of this pathway by
mutation of any of multiple genes is known to occur in the
majority of human cancers through various mechanisms
[38,39]. In a previous work [26], we demonstrated that MET,
through the activation of the PI3K/AKT pathway, induced
tumorigenesis and TRAIL resistance in NSCLC. Therefore, we
hypothesized that PDGFR-α/β, through the activation of the
AKT pathway should be involved in TRAIL-induced apoptosis.
Indeed, overexpression of miR-34a and miR-34c or
downregulation of PDGFR-α/β by siRNAs, highly increased the
response of semi-resistant NSCLC cells to TRAIL-induced
apoptosis. Importantly, combined treatment of a PDGFR
inhibitor with TRAIL, increased apoptosis and reduced cell
proliferation, as assessed by caspase 3/7 assay and MTT
assays. Taken together, the results suggest that combined
treatment of TRAIL with PDGFR inhibitors could sensitize a
subset of lung tumors, expressing the PDGF receptors, to the
drug. Moreover, it is well known that the PI3K/AKT, as well the
ERK1/2 pathways regulate cellular migration and invasion of
different cancers [40,41]. Here, we reported that miR-34a and
miR-34c overexpression or PDGFR-α/β silencing inhibited the
migration and invasion capacity of Calu-6 and H1703 cells,
compared to cells transfected with a scrambled miR or siRNA
control. Enforced expression of PDGFR-α or PDGFR-β partially
restored NSCLC migration and invasion supporting that the
regulation of the expression of these receptors by miR-34a/c
plays an important role in NSCLC tumorigenesis. However, we
recognize that other miR-34a/c targets including c-Met [16] and
AXL [42] could also be involved. While this manuscript was in
preparation Silber et al. reported that miR-34a expression was
lower in proneural gliomas compared to other tumor subtypes
and identified PDGFR-α as a direct target of miR-34a [43].
Here, we report that not only miR-34a but miR-34c also
downregulates PDGFR-α in NSCLC cells. Moreover, we
demonstrate that PDGFR-β is a miR-34a/c direct target while
we did not see any significant effect on the expression of
PDGFR-α and PDGFR-β after miR-34b enforced expression.
Remarkably, our study shows that inhibition or downregulation
of PDGFR-α and PDGFR-β by miR-34a/c antagonizes
tumorigenicity and increases sensitivity to TRAIL-induced cell
death with important therapeutic application for future anti-
tumor therapy of lung cancer.
Materials and Methods
Lung cancer cell lines and tissue samples
Human H460, A549, H1299, H1703 cell lines were grown in
RPMI medium containing 10% heat-inactivated fetal bovine
serum (FBS) and with 2mM L-glutamine and 100Uml-1
penicillin-streptomycin. Calu-6 cells were grown in MEM
supplemented with 10% fetal bovine serum, 2mM L-glutamine
and 100Uml-1 penicillin–streptomycin. 9 lung tumors (including
adenocarcinoma and squamous cell carcinoma) and their
normal counterparts were kindly provided by Dr. S.P. Nana-
Sinkam, Pulmonary, Allergy, Critical Care and Sleep Medicine,
The Ohio State University Comprehensive Cancer Center,
Columbus, OH. 48 lung normal and tumor tissue samples were
provided from the Department of Pathology, Ohio State
University. All human tissues were obtained according to a
protocol approved by the Ohio State Institutional Review
Board.
Luciferase assay
The 3’ UTRs of the human PDGFRA and PDGFRB genes,
were PCR amplified using the following primers:
PDGFR-α FW 5’ TCTAGACCG
GCCTGAGAAACACTATTTGTG 3’
PDGFR-α RW 5’
TCTAGAACATGAACAGGGGCATTCGTAATACA 3″
PDGFR-β FW 5’
TCTAGAAAAGAGGGCAAATGAGATCACCTCCTGCA 3’
PDGFR-β RW 5’
TCTAGATATTGAGAACCCACTCTCCCTCCTTGGA 3’
and cloned downstream of the Renilla luciferase stop codon
in pGL3 control vector (Promega). These constructs were used
to generate, by inverse PCR, the p3’-UTRs- mutant-plasmids
using the following primers:
PDGFR-α mut1 FW 5’
ACTGCCAAAACATTTATGACAAGCTGTATCGCCTCG 3’
PDGFR-α mut1 RW 5’
CGAGGCGATACAGCTTGTCATAAATGTTTTGGCAGT
PDGFR-αmut2 FW: 5’
ACTGCCAAAACATTTATGACAAGCTGTATGGTCGTTTATAT
TT 3’
PDGFR-αmut2 RW:5’
AAATATAAACGACCATACAGCTTGTCATAAATGTTTTGGCA
GT 3’
miR-34a/c Induce TRAIL Sensitivity
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PDGFR-β Mut FW 5'-
ATGGGGGTATGGTTTTGTCAGACCTAGCAGTGAC-3'
PDGFR-β Mut RW 5'-
GTCACTGCTAGGTCTGACAAAACCATACCCCCAT-3'
Calu-6 cells were cotransfected with 1μg of p3’UTR-PDGFR-
α, p3’UTR-PDGFR-β or with p3’UTRmut-PDGFR-α and
p3’UTRmut-PDGFR-β, 1 μg of a Renilla luciferase expression
construct pRL-TK (Promega) by using Lipofectamine 2000
(Invitrogen). Cells were harvested 24h post-transfection and
assayed with Dual Luciferase Assay (Promega) according to
the manufacturer’s instructions. Three independent
experiments were performed in triplicate.
Western Blot Analysis
Total proteins from NSCLC were extracted with
radioimmunoprecipitation assay (RIPA) buffer (0.15mM NaCl,
0.05mM Tris-HCl, pH 7.5, 1% Triton, 0.1% SDS, 0.1% sodium
deoxycholate and 1% Nonidet P40). Sample extract (50 μg)
was resolved on 7.5–12% SDS–polyacrylamide gels (PAGE)
using a mini-gel apparatus (Bio-Rad Laboratories) and
transferred to Hybond-C extra nitrocellulose. Membranes were
blocked for 1h with 5% nonfat dry milk in Tris-buffered saline
containing 0.05% Tween 20, incubated overnight with primary
antibody, washed and incubated with secondary antibody, and
visualized by chemiluminescence. The following primary
antibodies were used: anti-PDGFR-α, anti-PDGFR-β, anti-
ERK1/2, anti-p-ERKs, anti-pAKT, anti-total AKT, anti-GAPDH
antibodies (Cell Signaling). A secondary anti-rabbit or anti-
mouse immunoglobulin G (IgG) antibody peroxidase conjugate
(Chemicon) was used.
Real-time PCR
Real-time PCR was performed using a standard TaqMan
PCR Kit protocol on an Applied Biosystems 7900HT Sequence
Detection System (Applied Biosystems). The 10 μl PCR
reaction included 0.67 μl RT product, 1 μl TaqMan Universal
PCR Master Mix (Applied Biosystems), 0.2 mM TaqMan probe,
1.5 mM forward primer and 0.7 mM reverse primer. The
reactions were incubated in a 96-well plate at 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All
reactions were run in triplicate. The threshold cycle (CT) is
defined as the fractional cycle number at which the
fluorescence passes the fixed threshold. The comparative CT
method for relative quantization of gene expression (Applied
Biosystems) was used to determine miRNA expression levels.
The y axis represents the 2(-ΔCT), or the relative expression of
the different miRs. MiRs expression was calculated relative to
U44 and U48 rRNA. Experiments were carried out in triplicate
for each data point, and data analysis was performed by using
software (Bio- Rad).
Cell death and cell proliferation quantification
For detection of caspase 3/7 activity, cells were cultured in
96-well plates, in triplicate, treated with TRAIL (100-150ng/ml)
and analyzed using Caspase-Glo 3/7 Assay kit (Promega)
according to the manufacturer’s instructions. Continuous
variables are expressed as mean values ± standard deviation
(s.d.). Cell viability was examined with 3- (4,5-
dimethylthiazol-2-yl)-2,5-dipheniltetrazolium bromide (MTT)-
Cell Titer 96 AQueous One Solution Cell Proliferation Assay
(Promega), according to the manufacturer’s protocol.
Metabolically active cells were detected by adding 20 μl of MTT
to each well. After 1 h of incubation, the plates were analyzed
in a Multilabel Counter (Bio-Rad Laboratories).
Anti-PDGFR-α and anti-PDGFR-β siRNAs transfection
Cells were cultured to 50% confluence and transiently
transfected for 72h using Lipofectamine 2000 with 100 nM anti-
PDGFR-α and/or with 100nM anti-PDGFR-β SMARTpool
siRNAs or control siRNAs (Dharmacon), a pool of four target
specific 20–25 nt siRNAs designed to knock down gene
expression.
MiRNA locked nucleic acid in situ hybridization of
formalin fixed, paraffin-embedded tissue section
In situ hybridization (ISH) was carried out on deparaffinized
human lung tissues using previously published protocol[44],
which includes a digestion in pepsin (1.3 mg/ml) for 30
minutes. The sequence of the probe containing the dispersed
locked nucleic acid (LNA) modified bases with digoxigenin
conjugated to the 5’ end was: 5’
ACAACCAGCTAAGACACTGCCA 3’. The probe cocktail and
tissue miRNA were co-denatured at 60 °C for 5 minutes,
followed by hybridization at 37 °C overnight and a stringency
wash in 0.2X SSC and 2% bovine serum albumin at 4 °C for 10
minutes. The probe-target complex was seen due to the action
of alkaline phosphatase on the chromogen nitroblue
tetrazolium and bromochloroindolyl phosphate (NBT/BCIP).
Negative controls included the use of a probe, which should
yield a negative result in such tissues (scrambled miRNA). No
counterstain was used, to facilitate co-labeling for PDGFR-α
and PDGFR-β protein. After in situ hybridization for the
miRNAs, as previously described (Nuovo et al., 2009), the
slides were analyzed for immunohistochemistry using the
optimal conditions for PDGFR-α (1:100, cell conditioning for 30
minutes) and PDGFR-β (1:200, cell conditioning for 30
minutes). For the immunohistochemistry, we used the
Ultrasensitive Universal Fast Red or DAB systems from
Ventana Medical Systems. The percentage of tumor cells
expressing PDGFR-α, PDGFR-β and miR-34a, was then
analyzed with emphasis on co-localization of the respective
targets. Co-expression analysis was done with the Nuance
system (Cambridge Research Institute) per the manufacturer’s
recommendations.
Bioinformatics analysis
Bioinformatics analysis was performed by using these
specific programs:
Targetscan1, Pictar2, RNhybrid 3:
1 http://www.targetscan.org/
2 http://pictar.bio.nyu.edu/
3 http://bibiserv.techfak.uni-bielefeld.de/
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PDGFR-α and PDGFR-β plasmids
cDNA-PDGFR-α (Cat. Number MHS1010-9205933) and
cDNA-PDGFR-β (Cat. MHS1010-7430189) were purchased
from Open Biosystems. H460 TRAIL-sensitive cells were
transfected with 1μg of each plasmid and proliferation and
caspase 3/7 assays were performed as previously described.
Migration assay
Briefly, Calu-6 cells were transfected with pcDNA-PDGFR-α,
pcDNA-PDGFR-β and/or hsa-miR-34a and miR-34c,
respectively. 24h after transfection, 2x105 cells in MEM media
supplemented with 1% FBS were plated into the upper
chambers of the Migration assay and RPMI supplemented with
10% FBS were added into lower chambers to use as a
chemoattractant. After 24h, the upper chambers were
transferred into a new plate with detaching solutionscontaining
Calcein AM for 1 hour to measure the amount of the migrated
cells. The fluorescence was analyzed at an excitation
wavelength of 485 nm and an emission wavelength of 520nm.
Invasion assay
Briefly, 2x 105 Calu-6 cells transfected with pcDNA-PDGFR-
α, pcDNA-PDGFR-β and/or miR-34a and miR-34c in RPMI
supplemented with 1% FBS were plated into upper chambers
of Invasion assay with a 8-um pore size-polycarbonate
membrane. 700 μl of MEM supplemented with 10% FBS were
added into the lower chambers as a chemoattractant. After
36-48h, the upper chambers were transferred into a new plate
and were incubated with detaching solutions contained Calcein
AM for 1 hour to measure the amount of the invaded cells. The
fluorescence was analyzed at an excitation wavelength of 485
nm and an emission wavelength of 520nm.
Statistical analysis
Student’s t test was used to determine significance. All error
bars represent the standard error of the mean. Statistical
significance for all the tests, assessed by calculating P-value,
was < 0.05.
Supporting Information
File S1.  Figure S1, NSCLC cell lines analyzed and p53
status.  (a) A panel of 5 NSCLC cells with their p53 status is
reported. (b) qRT-PCR showing low expression of
miR-34a,-34b,-34c in 5 different NSCLC cells. Figure S2, Co-
expression analysis of miR-34a and PDGFR-α and PDGFR-
β in lung tumor samples. Tables reporting the percentage of
miR-34a, PDGFR-α and PDGFR-β expression observed in the
106 (PDGFR-α) and 107 (PDGFR-β) tumor samples analyzed
(A case with 10% of the tumor cells + was scored as +). Figure
S3, Enforced expression of miR-34a and miR-34c or PDGFR-
α/β silencing increases the response to TRAIL-induced
apoptosis and reduces tumorigenicity of NSCLC cell. (a)
Proliferation assay showing that miR-34a and -34c enforced
expression in Calu-6 and H1703 cells increases the response
to TRAIL-induced apoptosis. (b) MTT assay showing that
PDGFR-α or PDGFR-β silencing increases the response to
TRAIL-induced apoptosis. (c) PDGFR-α or PDGFR-β
overexpression in H460 TRAIL-sensitive cells decreases the
response to the drug as assessed by caspase 3/7 activity. (d)
Combined treatment of PDGFR inhibitor (20 μM) and TRAIL for
24h sensitizes NSCLC cells to TRAIL-induced apoptosis. * P<
0.05. Figure S4, PDGFR-α or PDGFR-β overexpression
reduces the response to TRAIL-induced apoptosis. (a)
Proliferation assay showing that miR-34a/c increase the
response to TRAIL-induced apoptosis. Co-transfection of
miR-34a/c with PDGFR-α/β significantly decreases the
response to the drug. (b) PDGFR-α/β enforced expression
along with miR-34a/c reduce the response to TRAIL-induced
apoptosis as assessed by caspase 3/7 assay. * P< 0.05.
(PDF)
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